TY - JOUR
T1 - In Vivo Animal Stroke Models
T2 - A Rationale for Rodent and Non-Human Primate Models
AU - Tajiri, Naoki
AU - Dailey, Travis
AU - Metcalf, Christopher
AU - Mosley, Yusef I.
AU - Lau, Tsz
AU - Staples, Meaghan
AU - van Loveren, Harry
AU - Kim, Seung U.
AU - Yamashima, Tetsumori
AU - Yasuhara, Takao
AU - Date, Isao
AU - Kaneko, Yuji
AU - Borlongan, Cesario V.
PY - 2013/6
Y1 - 2013/6
N2 - On average, every 4 min an individual dies from a stroke, accounting for one out of every 18 deaths in the United States. Approximately 795,000 Americans have a new or recurrent stroke each year, with just over 600,000 of these being first attack Roger et al. (Circulation, 125(1): 188-197, 2012). There have been multiple animal models of stroke demonstrating that novel therapeutics can help improve the clinical outcome. However, these results have failed to show the same outcomes when tested in human clinical trials. This review will discuss the current in vivo animal models of stroke, advantages and limitations, and the rationale for employing these animal models to satisfy translational gating items for examination of neuroprotective, as well as neurorestorative strategies in stroke patients. An emphasis in the present discussion of therapeutics development is given to stem cell therapy for stroke.
AB - On average, every 4 min an individual dies from a stroke, accounting for one out of every 18 deaths in the United States. Approximately 795,000 Americans have a new or recurrent stroke each year, with just over 600,000 of these being first attack Roger et al. (Circulation, 125(1): 188-197, 2012). There have been multiple animal models of stroke demonstrating that novel therapeutics can help improve the clinical outcome. However, these results have failed to show the same outcomes when tested in human clinical trials. This review will discuss the current in vivo animal models of stroke, advantages and limitations, and the rationale for employing these animal models to satisfy translational gating items for examination of neuroprotective, as well as neurorestorative strategies in stroke patients. An emphasis in the present discussion of therapeutics development is given to stem cell therapy for stroke.
KW - Animals
KW - Basic research
KW - Cerebral ischemia
KW - Clinical application
KW - Translational
UR - http://www.scopus.com/inward/record.url?scp=84877129320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877129320&partnerID=8YFLogxK
U2 - 10.1007/s12975-012-0241-2
DO - 10.1007/s12975-012-0241-2
M3 - Review article
C2 - 23682299
AN - SCOPUS:84877129320
SN - 1868-4483
VL - 4
SP - 308
EP - 321
JO - Translational Stroke Research
JF - Translational Stroke Research
IS - 3
ER -